Canaccord raised the firm's price target on AtriCure to $55 from $53 and keeps a Buy rating on the shares. The firm said they delivered a modest Q1 revenue beat, reiterated guidance, and showed better-than-expected profitability in Q1. The biggest takeaway from the call is that BoxX-NoAF, the company's prophylactic concomitant ablation + LAA in cardiac surgery RCT, is expected to complete enrollment by the end of 2026, one year ahead of initial expectations.
